CINECA IRIS Institutional Research Information System

SIMIELE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.228
EU - Europa 4.475
AS - Asia 1.100
AF - Africa 58
SA - Sud America 49
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 13
Totale 12.952
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.179
DK - Danimarca 1.388
IT - Italia 697
CN - Cina 696
IE - Irlanda 401
DE - Germania 358
FR - Francia 336
SE - Svezia 316
FI - Finlandia 222
UA - Ucraina 180
KR - Corea 131
GB - Regno Unito 128
AT - Austria 119
PL - Polonia 107
VN - Vietnam 72
IN - India 65
BE - Belgio 63
NL - Olanda 59
JP - Giappone 44
CA - Canada 38
AU - Australia 28
BR - Brasile 26
ES - Italia 23
ZA - Sudafrica 21
ID - Indonesia 16
TW - Taiwan 15
EG - Egitto 14
RU - Federazione Russa 13
TH - Thailandia 13
RO - Romania 12
CH - Svizzera 11
EU - Europa 11
GR - Grecia 9
CO - Colombia 8
TR - Turchia 8
CZ - Repubblica Ceca 6
HR - Croazia 6
MX - Messico 6
PK - Pakistan 6
SA - Arabia Saudita 6
CL - Cile 5
HK - Hong Kong 5
SG - Singapore 5
SN - Senegal 5
PE - Perù 4
PH - Filippine 4
UZ - Uzbekistan 4
AR - Argentina 3
BZ - Belize 3
HU - Ungheria 3
IL - Israele 3
NG - Nigeria 3
NO - Norvegia 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
TZ - Tanzania 3
AP - ???statistics.table.value.countryCode.AP??? 2
ET - Etiopia 2
IR - Iran 2
KE - Kenya 2
MA - Marocco 2
MY - Malesia 2
PY - Paraguay 2
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
HN - Honduras 1
IQ - Iraq 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MD - Moldavia 1
ME - Montenegro 1
MT - Malta 1
MU - Mauritius 1
MW - Malawi 1
NA - Namibia 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
TN - Tunisia 1
UG - Uganda 1
Totale 12.952
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.688
Chandler 656
Beijing 497
Dublin 399
Fairfield 333
Torino 300
Houston 269
Wilmington 239
Villeurbanne 228
Dearborn 200
Woodbridge 195
Nyköping 148
Princeton 143
Ashburn 140
Jacksonville 132
Medford 129
Seattle 124
Redwood City 110
Vienna 109
Cambridge 107
Warsaw 102
Pisa 61
Fremont 60
Brussels 46
Milan 45
Boston 42
Boardman 33
San Diego 30
Guangzhou 27
Dong Ket 26
Nanjing 26
Toronto 23
Hefei 20
Paris 20
Verona 20
Munich 18
Shanghai 18
Norwalk 17
Jakarta 13
Amsterdam 12
Kunming 12
Nürnberg 12
Dallas 11
Falls Church 11
Phoenix 11
Taipei 11
Omaha 10
Rome 10
Jinan 9
Silver Spring 9
Washington 9
Zhengzhou 9
Cairo 8
Des Moines 8
Edinburgh 8
Helsinki 8
Minneapolis 8
New York 8
Raritan 8
Buffalo 7
Chengdu 7
Mountain View 7
Tokyo 7
Göteborg 6
Los Angeles 6
Mumbai 6
Nanchang 6
San Mateo 6
Turin 6
Cape Town 5
Coimbatore 5
Durban 5
Düsseldorf 5
Hangzhou 5
Kharkiv 5
London 5
Louvain 5
Medellín 5
Ottawa 5
Piemonte 5
Rotterdam 5
San Jose 5
Santa Cruz 5
Sydney 5
Xian 5
Apo 4
Bethesda 4
Brescia 4
Bucharest 4
Central District 4
Fuzhou 4
Genoa 4
Henderson 4
Hyderabad 4
Indianapolis 4
Melbourne 4
Rio de Janeiro 4
Shenyang 4
Stockholm 4
Toulouse 4
Totale 8.189
Salva come PNG Salva come JPEG
Nome #
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 378
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 336
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 335
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 296
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 281
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 265
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 257
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 247
Raltegravir penetration in seminal plasma of healthy volunteers. 243
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 240
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 225
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 225
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 223
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 206
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 193
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 174
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 173
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 168
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 166
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 160
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 159
Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes 159
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 158
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 156
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 150
TCH-042 Stability Study of Ganciclovir in 0.9% Sodium Chloride in Different Types of Containers: Optimization of Resources 150
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 150
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 149
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 148
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 146
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification 146
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 145
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina 145
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 145
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 145
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 144
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 144
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 144
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 143
Cannabis FM2: optimization and standardization of galenic preparations. 142
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 141
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 140
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 140
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 139
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 139
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 137
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 136
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 134
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 134
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. 133
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 132
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 132
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 131
Sviluppo di protocolli operativi standard per l’ottimizzazione di preparazioni galeniche allestite con cannabis “FM2” 130
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 129
Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. 129
Prophylaxis drug monitoring of itraconazole and voriconazole in the paediatric onco-haematological setting 127
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 125
How effective are the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring? 125
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 123
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 123
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 113
Cannabinoids concentration variability in cannabis olive oil galenic preparations 104
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 94
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 91
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 90
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 87
Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. 86
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 86
Efavirenz pharmacogenetics in a cohort of Italian patients 79
Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots 79
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 78
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 78
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 77
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). 76
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 74
Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability 74
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 72
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 69
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 69
Class-specific relative genetic contribution for key antiretroviral drugs 64
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 64
Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole 63
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 63
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 62
Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml 60
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 58
Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms 57
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens 56
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 55
Determinants of Renal Tubular Dysfunction in HIV-positive Patients of More than 50 Years-old 54
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. 53
Therapeutic Drug Monitoring of Boosted Protease Inhibitors and 48-week Risk of Virological Failure 53
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. 50
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma 49
Single nucleotide polymorphisms of ABCB1 gene influence on intracellular concentrations of dasatinib. 48
Impact of Different Procedures of Galenic Formulations of Cannabis on Cannabinoids Contents 48
Single Nucleotide Polymorphisms of ABCB1 Gene Influence Daptomycin Pharmacokinetics in Adult Patients. [A-1769] 47
QUALITATIVE AND QUANTITATIVE EVALUATION OF DIFFERENT PHARMACEUTICAL PRODUCTS CONTAINING QUETIAPINE: BRAND VERSUS GENERIC 42
Totale 13.312
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.405
article - articoli 0
book - libri 0
conference - conferenze 9.109
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019845 0 0 84 34 36 71 48 110 39 100 208 115
2019/20203.025 73 71 59 233 374 569 257 133 132 281 363 480
2020/20211.515 354 51 42 86 88 77 76 49 105 123 105 359
2021/20223.317 324 298 318 346 249 277 355 285 205 98 287 275
2022/20232.035 208 111 43 184 202 529 156 147 215 41 134 65
2023/2024263 80 145 38 0 0 0 0 0 0 0 0 0
Totale 13.685